Literature DB >> 20416346

Immunological substance testing on human lymphatic micro-organoids in vitro.

Christoph Giese1, Annika Lubitz, Christian D Demmler, Jana Reuschel, Konstanze Bergner, Uwe Marx.   

Abstract

Pharmaceutical drugs and compounds used for consumer products may bear the risk of unexpected immuno-toxicological side effects, such as sensitization, allergy, anaphylaxis or immunogenicity. Modern biopharmaceuticals with high potency and target specificity, like antibodies and cytokines need to be tested for their therapeutical doses, their exposition regimens and their immune functionality prior to first-in-man applications. For the latter, existing in vitro tests and animal models do not sufficiently reflect the complexity and specificity of the human immune system. Even novel humanised animal models have limitations in their systemic reactions. Monolayer or suspended cell culture possesses neither tissue functionality nor organ physiology, and also cannot be used for long term culture and experiments. In contrast, solid tissue biopsies, e.g. tonsil preparations of tonsillitis patients typically show inflammatory artefacts and degrade in long term culture due to preparation-induced damage. The construction of tissue-like structures in vitro, so-called "micro-organoids", can overcome these limitations. Key structures of secondary lymphatic organs, e.g. lymph nodes or the spleen are the primary lymphatic follicles and germinal centres, in particular during the "activated state" of an inflammation or infection. To remodel lymphatic follicles, functional and structural cells, e.g. lymphoid cells derived from peripheral blood mononuclear cells (PBMCs) and stromal cells need to be combined with biogenic or artificial matrices and scaffolds to produce a suitable 3D tissue-mimicking environment. Therefore, a unique human lymph node model (HuALN) was designed to operate over several weeks, and allow long term and repeated drug exposure to induce and monitor both cellular and humoral immune responses. Cellular immunity is monitored, for example, by cytokine release patterns; humoral immunity is analysed, for example, by B cell activation, plasma cell formation and antibody secretion profiles (IgM and IgG). Moreover, cellular composition and micro-organoid formation are analysed by flow cytometry, histology and in situ imaging. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20416346     DOI: 10.1016/j.jbiotec.2010.03.001

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  25 in total

Review 1.  Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.

Authors:  Laura I Salazar-Fontana; Dharmesh D Desai; Tarik A Khan; Renuka C Pillutla; Sandra Prior; Radha Ramakrishnan; Jennifer Schneider; Alexandra Joseph
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

Review 2.  Preclinical models used for immunogenicity prediction of therapeutic proteins.

Authors:  Vera Brinks; Daniel Weinbuch; Matthew Baker; Yann Dean; Philippe Stas; Stefan Kostense; Bonita Rup; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-05-07       Impact factor: 4.200

Review 3.  Big insights from small volumes: deciphering complex leukocyte behaviors using microfluidics.

Authors:  Daniel Irimia; Felix Ellett
Journal:  J Leukoc Biol       Date:  2016-05-18       Impact factor: 4.962

Review 4.  Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors:  Regan Stephenson; Ankur Singh
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

5.  Substrate-bound CCL21 and ICAM1 combined with soluble IL-6 collectively augment the expansion of antigen-specific murine CD4+ T cells.

Authors:  Shimrit Adutler-Lieber; Irina Zaretsky; Helena Sabany; Elena Kartvelishvily; Ofra Golani; Benjamin Geiger; Nir Friedman
Journal:  Blood Adv       Date:  2017-06-15

6.  Modeling human adaptive immune responses with tonsil organoids.

Authors:  Lisa E Wagar; Ameen Salahudeen; Christian M Constantz; Ben S Wendel; Michael M Lyons; Vamsee Mallajosyula; Lauren P Jatt; Julia Z Adamska; Lisa K Blum; Neha Gupta; Katherine J L Jackson; Fan Yang; Katharina Röltgen; Krishna M Roskin; Kelly M Blaine; Kara D Meister; Iram N Ahmad; Mario Cortese; Emery G Dora; Sean N Tucker; Anne I Sperling; Aarti Jain; D Huw Davies; Philip L Felgner; Gregory B Hammer; Peter S Kim; William H Robinson; Scott D Boyd; Calvin J Kuo; Mark M Davis
Journal:  Nat Med       Date:  2021-01-11       Impact factor: 53.440

Review 7.  Applications of tumor chip technology.

Authors:  Stephanie J Hachey; Christopher C W Hughes
Journal:  Lab Chip       Date:  2018-09-26       Impact factor: 6.799

8.  Long-term immunologically competent human peripheral lymphoid tissue cultures in a 3D bioreactor.

Authors:  Igor Kuzin; Hongliang Sun; Safiekhatoon Moshkani; Changyong Feng; Athanasios Mantalaris; J H David Wu; Andrea Bottaro
Journal:  Biotechnol Bioeng       Date:  2011-02-18       Impact factor: 4.530

Review 9.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

Review 10.  The expanding world of tissue engineering: the building blocks and new applications of tissue engineered constructs.

Authors:  Pinar Zorlutuna; Nihal Engin Vrana; Ali Khademhosseini
Journal:  IEEE Rev Biomed Eng       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.